Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTX BioNTech	$97.88 +1.2%	$108.55	$81.20 ▼ $131.49	$23.26B	1.39	1.11 million shs	1.41 million shs
RDY Dr. Reddy's Laboratories	$14.64 -0.2%	$14.32	$12.26 ▼ $16.19	$12.24B	0.32	772,836 shs	903,367 shs
TAK Takeda Pharmaceutical	$15.08 -0.1%	$14.81	$12.80 ▼ $15.69	$48.05B	0.22	3.03 million shs	3.14 million shs
TEVA Teva Pharmaceutical Industries	$18.90 -5.2%	$17.35	$12.47 ▼ $22.80	$22.86B	0.72	9.92 million shs	12.25 million shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTX BioNTech	+1.18%	-4.66%	-13.78%	-6.75%	-20.68%
RDY Dr. Reddy's Laboratories	-0.10%	+2.59%	+2.92%	-3.89%	-8.95%
TAK Takeda Pharmaceutical	-0.20%	-1.21%	+0.60%	+1.28%	+2.59%
TEVA Teva Pharmaceutical Industries	-5.31%	-2.06%	+5.82%	+11.86%	+2.66%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTX BioNTech	$97.88 +1.2%	$108.55	$81.20 ▼ $131.49	$23.26B	1.39	1.11 million shs	1.41 million shs
RDY Dr. Reddy's Laboratories	$14.64 -0.2%	$14.32	$12.26 ▼ $16.19	$12.24B	0.32	772,836 shs	903,367 shs
TAK Takeda Pharmaceutical	$15.08 -0.1%	$14.81	$12.80 ▼ $15.69	$48.05B	0.22	3.03 million shs	3.14 million shs
TEVA Teva Pharmaceutical Industries	$18.90 -5.2%	$17.35	$12.47 ▼ $22.80	$22.86B	0.72	9.92 million shs	12.25 million shs

A Guide To High-Short-Interest Stocks

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTX BioNTech	+1.18%	-4.66%	-13.78%	-6.75%	-20.68%
RDY Dr. Reddy's Laboratories	-0.10%	+2.59%	+2.92%	-3.89%	-8.95%
TAK Takeda Pharmaceutical	-0.20%	-1.21%	+0.60%	+1.28%	+2.59%
TEVA Teva Pharmaceutical Industries	-5.31%	-2.06%	+5.82%	+11.86%	+2.66%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNTX BioNTech	2.76	Moderate Buy	$135.80	38.74% Upside
RDY Dr. Reddy's Laboratories	2.80	Moderate Buy	$16.95	15.82% Upside
TAK Takeda Pharmaceutical	2.00	Hold	N/A	N/A
TEVA Teva Pharmaceutical Industries	3.25	Buy	$24.71	30.76% Upside

Current Analyst Ratings Breakdown

Latest RDY, TAK, BNTX, and TEVA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/8/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$136.00
8/21/2025	TAK Takeda Pharmaceutical	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/15/2025	RDY Dr. Reddy's Laboratories	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/14/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$138.00 ➝ $136.00
8/5/2025	BNTX BioNTech	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$126.00 ➝ $134.00
8/5/2025	BNTX BioNTech	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Overweight	$170.00 ➝ $150.00
7/16/2025	BNTX BioNTech	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$127.00 ➝ $126.00
7/10/2025	BNTX BioNTech	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$132.00 ➝ $133.00
6/26/2025	TEVA Teva Pharmaceutical Industries	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$24.00 ➝ $23.00
6/25/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$138.00
6/16/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$145.00 ➝ $138.00

(Data available from 9/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNTX BioNTech	$2.98B	7.90	N/A	N/A	$87.61 per share	1.12
RDY Dr. Reddy's Laboratories	$3.81B	3.21	$1.03 per share	14.20	$4.73 per share	3.09
TAK Takeda Pharmaceutical	$30.09B	1.59	$3.17 per share	4.75	$14.39 per share	1.05
TEVA Teva Pharmaceutical Industries	$16.54B	1.31	$3.19 per share	5.92	$4.74 per share	3.99

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNTX BioNTech	-$719.92M	-$1.60	N/A	N/A	N/A	-12.20%	-1.84%	-1.59%	11/3/2025 (Estimated)
RDY Dr. Reddy's Laboratories	$663M	$0.66	22.17	17.85	5.92	16.99%	17.25%	11.63%	11/4/2025 (Estimated)
TAK Takeda Pharmaceutical	$712.33M	$0.30	50.27	9.14	N/A	3.20%	10.50%	5.10%	10/30/2025 (Estimated)
TEVA Teva Pharmaceutical Industries	-$1.64B	-$0.16	N/A	7.19	1.16	-0.95%	46.10%	7.18%	11/5/2025 (Estimated)

Latest RDY, TAK, BNTX, and TEVA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/4/2025	Q2 2025	BNTX BioNTech	-$1.41	-$1.60	-$0.19	-$1.82	$161.26 million	$306.46 million
7/30/2025	Q1 2026	TAK Takeda Pharmaceutical	$0.47	$0.52	+$0.05	$0.27	$7.96 billion	$7.45 billion
7/30/2025	Q2 2025	TEVA Teva Pharmaceutical Industries	$0.64	$0.66	+$0.02	$0.24	$4.34 billion	$4.18 billion
7/23/2025	Q1 25/26	RDY Dr. Reddy's Laboratories	$0.18	$0.20	+$0.02	$0.20	$88.27 billion	$988.82 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNTX BioNTech	N/A	N/A	N/A	N/A	N/A
RDY Dr. Reddy's Laboratories	$0.07	0.48%	N/A	10.61%	N/A
TAK Takeda Pharmaceutical	$0.55	3.65%	N/A	183.33%	N/A
TEVA Teva Pharmaceutical Industries	N/A	N/A	N/A	N/A	N/A

Latest RDY, TAK, BNTX, and TEVA Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/30/2025	RDY Dr. Reddy's Laboratories	annual	$0.0915	0.623832253665189%	7/25/2025	7/10/2025	8/6/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNTX BioNTech	0.01	8.61	8.48
RDY Dr. Reddy's Laboratories	0.01	1.89	1.36
TAK Takeda Pharmaceutical	0.60	1.16	0.59
TEVA Teva Pharmaceutical Industries	2.45	1.06	0.77

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNTX BioNTech	15.52%
RDY Dr. Reddy's Laboratories	3.85%
TAK Takeda Pharmaceutical	9.17%
TEVA Teva Pharmaceutical Industries	54.05%

Insider Ownership

Company	Insider Ownership
BNTX BioNTech	19.20%
RDY Dr. Reddy's Laboratories	2.00%
TAK Takeda Pharmaceutical	0.04%
TEVA Teva Pharmaceutical Industries	0.55%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNTX BioNTech	6,772	240.40 million	194.24 million	Optionable
RDY Dr. Reddy's Laboratories	27,811	834.92 million	818.23 million	Optionable
TAK Takeda Pharmaceutical	47,455	3.18 billion	3.18 billion	Optionable
TEVA Teva Pharmaceutical Industries	36,830	1.15 billion	1.14 billion	Optionable

RDY, TAK, BNTX, and TEVA Headlines

Recent News About These Companies

Drugmaker Corcept must face Teva lawsuit over mifepristone 'monopoly' for rare disorder

September 15 at 12:14 PM | reuters.com

Intech Investment Management LLC Has $5.37 Million Stock Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

September 14 at 4:45 AM | marketbeat.com

Plato Investment Management Ltd Sells 24,495 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

September 14 at 4:28 AM | marketbeat.com

Teva Pharmaceutical Industries Ltd. $TEVA Shares Purchased by Amundi

September 12, 2025 | marketbeat.com

Zimmer Partners LP Purchases New Position in Teva Pharmaceutical Industries Ltd. $TEVA

September 11, 2025 | marketbeat.com

Here’s Why Sound Shore Fund Added Teva Pharmaceutical Industries Limited (TEVA) in Q2

September 10, 2025 | insidermonkey.com

Axiom Investors LLC DE Makes New Investment in Teva Pharmaceutical Industries Ltd. $TEVA

September 10, 2025 | marketbeat.com

Clearline Capital LP Takes Position in Teva Pharmaceutical Industries Ltd. $TEVA

September 10, 2025 | marketbeat.com

Teva Pharmaceutical Industries Limited (TEVA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

September 9, 2025 | seekingalpha.com

Adage Capital Partners GP L.L.C. Cuts Stock Position in Teva Pharmaceutical Industries Ltd. $TEVA

September 9, 2025 | marketbeat.com

Zacks Research Issues Pessimistic Forecast for TEVA Earnings

September 9, 2025 | marketbeat.com

Zacks Research Has Pessimistic Outlook of TEVA Q3 Earnings

September 9, 2025 | americanbankingnews.com

Parsifal Capital Management LP Sells 169,814 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

September 8, 2025 | marketbeat.com

Graham Capital Management L.P. Cuts Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

September 8, 2025 | marketbeat.com

Teva Pharmaceutical Industries Ltd. $TEVA Shares Acquired by NWI Management LP

September 7, 2025 | marketbeat.com

Ion Asset Management Ltd. Acquires 2,383,500 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

September 7, 2025 | marketbeat.com

Canada Pension Plan Investment Board Has $2.32 Million Stock Position in Teva Pharmaceutical Industries Ltd. $TEVA

September 7, 2025 | marketbeat.com

Teva Pharmaceutical Industries Ltd. $TEVA is Cutter Capital Management LP's 10th Largest Position

September 6, 2025 | marketbeat.com

Banque Transatlantique SA Makes New $473,000 Investment in Teva Pharmaceutical Industries Ltd. $TEVA

September 6, 2025 | marketbeat.com

Alyeska Investment Group L.P. Decreases Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

September 6, 2025 | marketbeat.com

First Manhattan CO. LLC. Has $333,000 Position in Teva Pharmaceutical Industries Ltd. $TEVA

September 6, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

RDY, TAK, BNTX, and TEVA Company Descriptions

BioNTech NASDAQ:BNTX

$97.88 +1.14 (+1.18%)

Closing price 09/15/2025 04:00 PM Eastern

Extended Trading

$97.55 -0.33 (-0.34%)

As of 09/15/2025 07:52 PM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Dr. Reddy's Laboratories NYSE:RDY

$14.64 -0.03 (-0.17%)

Closing price 09/15/2025 03:59 PM Eastern

Extended Trading

$14.60 -0.04 (-0.27%)

As of 09/15/2025 06:04 PM Eastern

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Takeda Pharmaceutical NYSE:TAK

$15.08 -0.02 (-0.13%)

Closing price 09/15/2025 03:59 PM Eastern

Extended Trading

$15.03 -0.05 (-0.32%)

As of 09/15/2025 07:46 PM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

Teva Pharmaceutical Industries NYSE:TEVA

$18.90 -1.03 (-5.17%)

Closing price 09/15/2025 03:59 PM Eastern

Extended Trading

$18.93 +0.04 (+0.19%)

As of 09/15/2025 07:57 PM Eastern

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RDY, TAK, BNTX, and TEVA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RDY, TAK, BNTX, and TEVA Earnings

Compare Dividends

Latest RDY, TAK, BNTX, and TEVA Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RDY, TAK, BNTX, and TEVA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RDY, TAK, BNTX, and TEVA Company Descriptions

BioNTech NASDAQ:BNTX

Dr. Reddy's Laboratories NYSE:RDY

Takeda Pharmaceutical NYSE:TAK

Teva Pharmaceutical Industries NYSE:TEVA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools